Gilead Sciences will go to court this week to argue that it does not need to pay the US Government a share of the profits it has made on the use of its HIV drugs for pre-e
More than three years after it was first rejected by the FDA, Takeda's subcutaneous (SC) formulation of Entyvio has been resubmitted as a maintenance therapy for ulcerativ
Biosimilar competition to AbbVie’s cash-cow product Humira ramped up in the first quarter, but more worrying for the company was disappointing growth among the products it
For our final March hires roundup instalment, we have our “pharma-adjacent” roundup which includes CROs, clinical trial software companies, manufacturing organisations, suppliers, non-profi
Eli Lilly’s new therapy Mounjaro has aced a second phase 3 trial as a treatment of obesity or being overweight, this time in patients with type 2 diabetes.
The reporting week has started with reports that activist investor Starboard Value has amassed a $1 billion stake in pharma group Pfizer and wants strategic changes to restore growth.